BioAsia 2015: Can India Move Beyond Its Low-cost Advantage?
This article was originally published in PharmAsia News
Executive Summary
Drug discovery partnerships in India are at the cusp of big changes. Global innovators have moved away from considering India as a low-cost destination, instead looking beyond just outsourcing clinical development projects or in-licensing compounds. They are keen to forge long-term relationships with academia and also to look at model start-ups to spur a culture of innovation.